We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
In mid November, US drugmaker Moderna announced its experimental COVID-19 vaccine was 94.5% effective in preventing the virus. The news comes just a week after Pfizer's vaccine revealed a 90% accuracy rate.
Moderna (MRNA) is a US pharmaceutical and biotechnology company. The company focuses on messenger RNA (mRNA) technology and was among the first to develop a vaccination against COVID-19. Moderna was founded in 2010 and its headquarters are in Cambridge, Massachusetts in the USA.
Our top pick for
US stocks
Our top pick for
Long-term investing
Our top pick for
Low-cost broker
| 52-week range | US$115.61 - US$497.49 |
|---|---|
| 50-day moving average | US$139.1888 |
| 200-day moving average | US$219.6321 |
| Target price | US$219.33 |
| PE ratio | 4.2733 |
| Dividend yield | US$0 (0%) |
| Earnings per share (TTM) | US$34.016 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $142.19
| 1 week (2022-06-22) | 4.50% |
|---|---|
| 1 month (2022-05-25) | 8.67% |
| 1 year (2021-06-29) | -39.35% |
|---|---|
| 2 years (2020-06-29) | 129.04% |
| 3 years (2019-06-28) | 871.24% |
Valuing Moderna stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Moderna's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Moderna's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Moderna shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Moderna's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$16.6 billion (£13.6 billion).
The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | US$22.6 billion |
|---|---|
| Operating margin TTM | 71.93% |
| Gross profit TTM | US$13.9 billion |
| Return on assets TTM | 50.42% |
| Return on equity TTM | 139.99% |
| Profit margin | 64.77% |
| Book value | 42.688 |
| Market capitalisation | US$57.8 billion |
TTM: trailing 12 months
We're not expecting Moderna to pay a dividend over the next 12 months.
Over the last 12 months, Moderna's shares have ranged in value from as little as US$115.61 up to US$497.49. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.6928. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing Kincora Copper shares.
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
Steps to owning and managing Leo lithium shares.
